Added
Updated
BioMimetix Pharmaceutical
BioMimetix Inc., a Colorado-based biopharmaceutical firm, develops compounds for radiation toxicity treatment in cancer care.
Founded
2011BioMimetix Inc., a Colorado-based biopharmaceutical firm, develops compounds for radiation toxicity treatment in cancer care.
BioMimetix Inc., founded in 2013 and based in Greenwood Village, Colorado, is a pioneering biopharmaceutical firm dedicated to developing innovative treatments for cancer patients. The company's core mission is to advance healthcare by creating compounds that mitigate radiation toxicity during cancer treatment. Their flagship product, BMX-001, is a redox-active metalloporphyrin designed to protect normal tissues from radiation damage while enhancing the effectiveness of cancer therapies.
Notable figures associated with BioMimetix include leading researchers and industry experts who have significantly contributed to the field of oncology. The company has garnered attention from key investors in the biopharmaceutical sector, supporting its groundbreaking work. BioMimetix's achievements include promising clinical trial results and numerous scientific publications, underscoring its potential to revolutionize cancer treatment and improve patient outcomes.
Companies similar to BioMimetix Pharmaceutical include Endomimetics, BioCurity Pharmaceuticals, LipimetiX and Mimetics.
BioMimetix Pharmaceutical was founded in 2011.
BioMimetix Pharmaceutical's headquarters is located in Greenwood Village, CO, US.
BioMimetix Pharmaceutical's most recent funding round was for $2M (USD) in July 2011.
As of Jul 26, 2011, BioMimetix Pharmaceutical has raised a total of $2M (USD).
BioMimetix Pharmaceutical has 11 employees as of Feb 5, 2024.
LipimetiX
